Reading CHRS? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CHRS free→Reading CHRS? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CHRS free→QuarterlyIQ Insights · CHRS
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Changes in Registrant’s Certifying Accountant. (a) Dismissal of Previous Independent Registered Public Accounting Firm On June 12, 2026, the Audit Committee (the “Audit Committee”) of the Board of Directors of Coherus Oncology, Inc. (the “Company”) dismissed Ernst & Young LLP (“EY”) as the Company’s independent registered public accounting firm, with dismissal effective as of such date. The reports of EY on the consolidated financial statements of the Company as of and for the fiscal years en…
of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Other Events. On February 12, 2026, Coherus Oncology, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with TD Securities (USA) LLC, Guggenheim Securities, LLC and Oppenheimer & Co. Inc. as representatives (the “Representatives”) of the several underwriters named therein (collectively, the “Underwriters”), pursuant to which the Company agreed to issue and sell an aggregate of 28,600,000 shares (the “Firm Shares”) of its common stock, par value $0.00…
Other Events. On January 23, 2026, Coherus Oncology, Inc. (the “Company”) filed a prospectus supplement relating to its Sales Agreement, dated November 8, 2022, by and between the Company and Cowen and Company LLC, as amended by the Amendment No. 1 to Sales Agreement, dated May 15, 2023 and Amendment No. 2 to Sales Agreement, dated September 11, 2023, which was assigned to TD Securities (USA) LLC (“TD Cowen”) (the “Sales Agreement”). Pursuant to the Sales Agreement, the Company may offer and…
of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), or incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific referen…
Other Events. Coherus Oncology, Inc. (the “Company”) is filing this Current Report on Form 8-K (this “Form 8-K”), including Exhibit 99.1, solely to recast certain financial information and related disclosures included in the Company’s Annual Report on Form 10-K for the fiscal year ending December 31, 2024 originally filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 17, 2025 (the “2024 Form 10-K”) to provide retrospective discontinued operations presentation for the y…
of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On June 30, 2025, Coherus Oncology, Inc. (the “Company”) received a deficiency notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below $1.00 per share, the minimum closing bid price required by the…
of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Intention not to Stand for Re-election On April 22, 2025, Mark D. Stolper, a member of the Board of Directors (the “Board”) of Coherus BioSciences, Inc. (the “Company”), notified the Board of his intention not to stand for re-election to the Board for an additional three-year term at the Company's 2025 Annual Meeting of Stockholders (the “2…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Departure of Paul Reider as Chief Commercial Officer Paul Reider notified Coherus BioSciences, Inc. (the “Company”) on April 16, 2025 of his resignation as Chief Commercial Officer and employee of the Company effective on April 30, 2025 in order to pursue other opportunities following the completion of the Company’s divestiture of its UDENYCA f…
Other Events. On April 1, 2025, the Company issued a press release (the “Press Release”) announcing that it had entered into privately negotiated transactions (the “Repurchases”) with certain holders of its Convertible Notes, pursuant to which the Company agreed to repurchase approximately $170 million aggregate principal amount of the Convertible Notes from such holders at a cash repurchase price equal to 100% of their principal amount, together with the accrued and unpaid interest to, but…
Entry into a Material Definitive Agreement. On March 31, 2025, in connection with the privately negotiated repurchase transactions described in
of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Other Events On January 28, 2025, Coherus BioSciences, Inc., a Delaware corporation (the “Company”), filed with the U.S. Securities and Exchange Commission (the “SEC”) a definitive proxy statement (the “Proxy Statement”) relating to the special meeting of stockholders (the “Special Meeting”) to be held on March 11, 2025, at 1:30 p.m. Pacific Time, to, among other things, approve the sale of the Company’s UDENYCA (pegfilgrastim-cbqv) franchise (the “Transaction”) to Intas Pharmaceuticals L…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.